WO2004000209A2 - Administration of therapeutic viruses - Google Patents

Administration of therapeutic viruses Download PDF

Info

Publication number
WO2004000209A2
WO2004000209A2 PCT/US2003/016474 US0316474W WO2004000209A2 WO 2004000209 A2 WO2004000209 A2 WO 2004000209A2 US 0316474 W US0316474 W US 0316474W WO 2004000209 A2 WO2004000209 A2 WO 2004000209A2
Authority
WO
WIPO (PCT)
Prior art keywords
virus
surface area
dose
per square
square meter
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/016474
Other languages
French (fr)
Other versions
WO2004000209A3 (en
Inventor
Robert M. Lorence
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellstat Biologics Corp
Original Assignee
Wellstat Biologics Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EP03761032A priority Critical patent/EP1539230A4/en
Priority to NZ537255A priority patent/NZ537255A/en
Priority to AU2003243307A priority patent/AU2003243307B2/en
Priority to CA002489523A priority patent/CA2489523A1/en
Priority to US10/518,732 priority patent/US20050220818A1/en
Priority to MXPA04012881A priority patent/MXPA04012881A/en
Priority to JP2004515715A priority patent/JP2006511450A/en
Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp
Publication of WO2004000209A2 publication Critical patent/WO2004000209A2/en
Priority to IL16586004A priority patent/IL165860A0/en
Anticipated expiration legal-status Critical
Publication of WO2004000209A3 publication Critical patent/WO2004000209A3/en
Priority to US12/409,711 priority patent/US20090180993A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity

Definitions

  • Therapeutic viruses are used for the treatment of cancer and other diseases (Kirn, et al., Trends Mol. Med., 8(4) (Suppl.):S68-S73, 2002 (review)).
  • therapeutic viruses are associated with certain toxic effects, which limit the amount of virus that can be administered.
  • Pecora et al., J. Clin. Oncol. (May 2002) 20(9):2251-2266.
  • This invention provides a method for administering a therapeutic virus to a subject in one or more cycles, wherein at least one cycle comprises administering sequentially two or more desensitization doses of the virus followed by administering one or more escalated doses of the virus, wherein: the virus is a negative-stranded RNA virus; the amount of the virus in the second and any subsequent desensitization dose is not less than the amount of the virus in the preceding desensitization dose; and the amount of the virus in each of the one or more escalated doses is higher than the amount of virus in each of the desensitization doses.
  • This invention provides a method for administering a dose of a therapeutic virus to a subject, wherein: the virus is a negative-stranded RNA virus; the dose is the first dose in a cycle comprising one or more doses of the virus; the dose is administered over an administration time period of up to 24 hours; and the dose is administered at a rate of up to 3.0 x 10 9 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • This invention provides a method for administering a dose of a therapeutic virus to a subject, wherein: the virus is a negative-stranded RNA virus; the dose is the second or subsequent dose in a cycle comprising two or more doses of the virus; the dose is administered over an administration time period of up to 24 hours; and the dose is administered at a rate of up to 5.0 x 10 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • This invention is based on the finding that the toxicities of a therapeutic virus, for example a mesogenic strain of Newcastle Disease Virus, can be decreased by at least two introductory desensitization doses of the virus. It is also based on the finding that such toxicities can be decreased by limiting the rate at which the virus is administered.
  • a therapeutic virus for example a mesogenic strain of Newcastle Disease Virus
  • the transitional term "comprising” is open-ended. A claim utilizing this term can contain elements in addition to those recited in such claim. Thus, for example, the claims can read on treatment regimens that also include other theapeutic agents or therapeutic virus doses not specifically recited therein, as long as the recited elements or their equivalent are present.
  • NDV Newcastle Disease Virus
  • DLT is an abbreviation for dose limiting toxicity.
  • plaque-forming unit PFU means one infectious virus particle.
  • BPFU means billion PFUs.
  • PP means plaque-purified.
  • PPMK107 means plaque-purified Newcastle Disease virus strain MK107.
  • PFU/m 2 which is a standard unit for expressing dosages, means PFUs per square meter of patient surface area.
  • replication- competent virus refers to a virus that produces infectious progeny in cancer cells.
  • the therapeutic virus utilized can be of low (lentogenic), moderate (mesogenic) or high (velogenic) virulence.
  • the level of virulence is determined in accordance with the Mean Death Time in Eggs (MDT) test. (Alexander, "Chapter 27: Newcastle Disease” in Laboratory Manual for the Isolation and Identification of Avian Pathogens, 3 rd ed., Purchase, et al. eds. (Kendall Hunt, Iowa), page 117.)
  • Viruses are classified by the MDT test as lentogenic (MDT>90 hours); mesogenic (MDT from 60-90 hours); and velogenic (MDT ⁇ 60 hours).
  • a regimen comprising two or more desensitization doses followed by one or more escalated doses can be carried out in one or more than one treatment cycle.
  • desensitization regimen is followed for at least the first cycle of treatment, and more preferably for all cycles of treatment.
  • the method can be utilized with any conventional therapy utilizing a therapeutic virus.
  • therapies include oncolytic viruses for the treatment of cancer and the use of viruses in gene therapy, as described for example in WO 94/25627, WO 00/62735, and Kirn, et al., Trends Mol. Med., 8(4) (Suppl.):S68-S73, 2002 (review).
  • the virus is a replication-competent oncolytic virus.
  • it is a Paramyxovirus, for example a Newcastle Disease Virus.
  • a mesogenic strain is preferred.
  • the oncolytic virus is a Rhabdovirus, for example a Vesicular Stomatitis Virus.
  • the first desensitizing dose is at least 1 10 PFU per square meter of patient surface area; at least 3 x 10 8 PFU per square meter of patient surface area; or at least 1 x 10 9 PFU per square meter of patient surface area.
  • the second desensitizing dose is at least 3 x 10 9 PFU per square meter of patient surface area; at least 5.9 x 10 9 PFU per square meter of patient surface area; or at least 1.2 x 10 10 PFU per square meter of patient surface area.
  • the escalated doses are at least 3 x 10 9 PFU per square meter of patient surface area; at least 5.9 x 10 9 PFU per square meter of patient surface area; at least 1.2 x 10 10 PFU per square meter of patient surface area; at least 2.4 x 10 10 PFU per square meter of patient surface area; at least 4.8 x 10 10 PFU per square meter of patient surface area; at least 9.6 x 10 10 PFU per square meter of patient surface area; at least 1.2 x 10 11 PFU per square meter of patient surface area; at least 1.44 x 10 11 PFU per square meter of patient surface area; or at least 1.96 x 10 11 PFU per square meter of patient surface area.
  • the number of desensitization doses that can be administered is two or three.
  • the third desensitization dose is at least 3 x 10 9 PFU per square meter of patient surface area; at least 5.9 x 10 9 PFU per square meter of patient surface area; or at least 1.2 x 10 10 PFU per square meter of patient surface area.
  • multi- step desensitization can be combined with controlled-rate administration of a given dose of the therapeutic virus.
  • the first desensitization dose is administered over an administration time period of up to 24 hours; and is administered at a rate of up to 3.0 x 10 9 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • the first desensitization dose is administered at a rate of up to 6.7 x 10 8 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period; or up to 3.3 x 10 8 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • one or more doses selected from the second desensitization dose, a subsequent desensitization dose, if any, and an escalated dose is administered over an administration time period of less than 24 hours; and is administered at a rate of up to 5.0 x 10 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • the second desensitization dose, a subsequent desensitization dose or an escalated dose is administered at a rate of up to 2.0 x 10 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • the amount of the virus in the second and any subsequent desensitization dose can be equal to or, preferably, greater than the amount of the virus in the preceding desensitization dose.
  • the therapeutic virus can be administered by any conventional route, for example those disclosed in WO 00/62735. Intravenous administration is preferred.
  • the subject can be a human or a non-human mammal.
  • the method can be utilized with any conventional therapy utilizing a therapeutic virus.
  • therapies include oncolytic viruses for the treatment of cancer and the use of viruses in gene therapy, as described for example in WO 94/25627, WO 00/62735, and Kirn, et al., Trends Mol. Med., 8(4) (Suppl.):S68-S73, 2002 (review).
  • the virus is a replication-competent oncolytic virus.
  • it is a Paramyxovirus, for example a Newcastle Disease Virus.
  • a mesogenic strain is preferred.
  • the oncolytic virus is a Rhabdovirus, for example a Vesicular Stomatitis Virus.
  • the therapeutic virus in accordance with methods of this invention in which the rate of administration of a therapeutic virus dose is controlled, can be administered by any conventional route, for example those disclosed in WO 00/62735. Intravenous administration is preferred.
  • the subject in accordance with methods of this invention in which the rate of administration of a therapeutic virus dose is controlled, can be a human or a non-human mammal.
  • the administration time period is from 1 hour to 24 hours. In a more specific embodiment, the administration time period is from 3 hours to 24 hours.
  • the rate of administration of the first dose in a cycle of the therapeutic virus is controlled, and especially when the virus is a replication-competent, mesogenic strain of Newcastle Disease Virus
  • the rate of the first dose is up to 6.7 x 10 8 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period; or up to 3.3 x 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • the amount of virus in the first dose is at least 1 x 10 8 PFU per square meter of patient surface area; at least 3 x 10 8 PFU per square meter of patient surface area; or at least 1 x 10 9 PFU per square meter of patient surface area.
  • the rate of administration of the second or subsequent dose in a cycle of the therapeutic virus is controlled, and especially when the virus is a replication-competent, mesogenic strain of Newcastle Disease Virus, the rate of the second or subsequent dose is up to 2.0 x 10 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
  • the amount of virus in the second or subsequent dose is at least 3 x 10 9 PFU per square meter of patient surface area; at least 5.9 x 10 9 PFU per square meter of patient surface area; at least 1.2 x 10 10 PFU per square meter of patient surface area; at least 2.4 x 10 10 PFU per square meter of patient surface area; at least 4.8 x 10 10 PFU per square meter of patient surface area; at least 9.6 x 10 10 PFU per square meter of patient surface area; at least 1.2 x 10 11 PFU per square meter of patient surface area; at least 1.44 x 10 11 PFU per square meter of patient surface area; or at least 1.96 x 10 u PFU per square meter of patient surface area.
  • the volume, and hence the concentration, for a therapeutic virus dose generally is not critical. Nevertheless, when choosing a volume the rate of administration should be taken into account. If the volume is too small, it may be difficult to infuse over a long period of time. When administration is to take place over a time period of thirty minutes or more, it has been found convenient to dilute virus doses of less than 4.8 x 10 10 PFU/m 2 in 25 ml to 100 ml or even greater volumes of saline. For virus doses of greater than 4.8 x 10 10 PFU/m 2 dilution in 50 ml to 250 ml or even greater volumes of saline is convenient.
  • PPMK107 a mesogenic Newcastle disease virus strain, as disclosed in WO 00/62735, was given intravenously 3 times per week for 1 week cycled every 4 weeks. Patients were given an initial desensitization dose of 1.2 x 10 10 PFU/m 2 followed by higher doses ranging from 2.4 to 9.6 x 10 10 PFU/m 2 . This approach therefore used a "Single Step Desensitization". Doses 2-3 were constant in each patient, but escalated by cohort (Table 1).
  • the first dose of 1.2 x 10 10 PFU/m 2 was administered over 10 minutes, the doses of 2.4 to 4.8 x 10 10 PFU/m 2 was given over 10 minutes and the dose of 9.6 x 10 10 PFU/m 2 was given over 10 to 20 minutes.
  • PPMK107 a mesogenic Newcastle disease virus strain, as disclosed in WO 00/62735, is given intravenously, 6 times in 2 weeks, cycled every 21 days. The first dose is given over 3 hours and subsequent doses are given over 1 hour. Three different dose levels are included in this example. At each dose level, the 1 st dose is a desensitizing dose for the higher doses. Doses 2-6 were constant in each patient (Table 4). This approach therefore uses a "Single Step Desensitization"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Two or more desensitization doses of a therapeutic virus are administered, followed by one or more escalated doses of the virus. In addition, the rate at which a therapeutic virus is administered can be controlled.

Description

ADMINISTRATION OF THERAPEUTIC VIRUSES
BACKGROUND OF THE INVENTION
Therapeutic viruses (either oncolytic viruses or replication-incompetent viruses for gene therapy) are used for the treatment of cancer and other diseases (Kirn, et al., Trends Mol. Med., 8(4) (Suppl.):S68-S73, 2002 (review)). However the administration of therapeutic viruses is associated with certain toxic effects, which limit the amount of virus that can be administered. (Pecora, et al., J. Clin. Oncol. (May 2002) 20(9):2251-2266.)
The administration of a desensitizing dose of an oncolytic virus before higher subsequent doses is disclosed in WO 00/62735 (pages 35-36). See also Pecora, et al., J. Clin. Oncol. (May 2002) 20(9):2251-2266; and Bergsland, et al., J. Clin. Oncol. (May 2002) 20(9): 2220-2222.
The administration of oncolytic viruses using an intravenous pump, syringe pump, intravenous drip or slow injection over the course of 4 minutes to 24 hours, for example over the course of 20 to 60 minutes, is disclosed in WO 00/62735 (page 36, lines 16-19).
It would be desirable to find means of further minimizing such negative side effects. The minimization side effects is valuable in its own right, and also because it could make possible the administration of higher doses of the theraepeutic virus, and with such higher doses the possibility of improved therapeutic effect.
SUMMARY OF THE INVENTION
This invention provides a method for administering a therapeutic virus to a subject in one or more cycles, wherein at least one cycle comprises administering sequentially two or more desensitization doses of the virus followed by administering one or more escalated doses of the virus, wherein: the virus is a negative-stranded RNA virus; the amount of the virus in the second and any subsequent desensitization dose is not less than the amount of the virus in the preceding desensitization dose; and the amount of the virus in each of the one or more escalated doses is higher than the amount of virus in each of the desensitization doses.
This invention provides a method for administering a dose of a therapeutic virus to a subject, wherein: the virus is a negative-stranded RNA virus; the dose is the first dose in a cycle comprising one or more doses of the virus; the dose is administered over an administration time period of up to 24 hours; and the dose is administered at a rate of up to 3.0 x 109 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
This invention provides a method for administering a dose of a therapeutic virus to a subject, wherein: the virus is a negative-stranded RNA virus; the dose is the second or subsequent dose in a cycle comprising two or more doses of the virus; the dose is administered over an administration time period of up to 24 hours; and the dose is administered at a rate of up to 5.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
This invention is based on the finding that the toxicities of a therapeutic virus, for example a mesogenic strain of Newcastle Disease Virus, can be decreased by at least two introductory desensitization doses of the virus. It is also based on the finding that such toxicities can be decreased by limiting the rate at which the virus is administered.
DETAILED DESCRIPTION OF THE INVENTION
As used herein the transitional term "comprising" is open-ended. A claim utilizing this term can contain elements in addition to those recited in such claim. Thus, for example, the claims can read on treatment regimens that also include other theapeutic agents or therapeutic virus doses not specifically recited therein, as long as the recited elements or their equivalent are present. As used herein "NDV" is an abbreviation for Newcastle Disease Virus. As used herein "DLT" is an abbreviation for dose limiting toxicity. As used herein the term "plaque-forming unit" (PFU) means one infectious virus particle. As used herein "BPFU" means billion PFUs. As used herein "PP" means plaque-purified. Thus, for example PPMK107 means plaque-purified Newcastle Disease virus strain MK107. As used herein "PFU/m2", which is a standard unit for expressing dosages, means PFUs per square meter of patient surface area. As used herein the term "replication- competent" virus refers to a virus that produces infectious progeny in cancer cells.
In accordance with the methods of this invention the therapeutic virus utilized can be of low (lentogenic), moderate (mesogenic) or high (velogenic) virulence. The level of virulence is determined in accordance with the Mean Death Time in Eggs (MDT) test. (Alexander, "Chapter 27: Newcastle Disease" in Laboratory Manual for the Isolation and Identification of Avian Pathogens, 3rd ed., Purchase, et al. eds. (Kendall Hunt, Iowa), page 117.) Viruses are classified by the MDT test as lentogenic (MDT>90 hours); mesogenic (MDT from 60-90 hours); and velogenic (MDT<60 hours).
In accordance with the multi-step desensitization method of this invention, a regimen comprising two or more desensitization doses followed by one or more escalated doses can be carried out in one or more than one treatment cycle. Preferably such desensitization regimen is followed for at least the first cycle of treatment, and more preferably for all cycles of treatment.
In accordance with the multi-step desensitization method of this invention, the method can be utilized with any conventional therapy utilizing a therapeutic virus. Examples of such therapies include oncolytic viruses for the treatment of cancer and the use of viruses in gene therapy, as described for example in WO 94/25627, WO 00/62735, and Kirn, et al., Trends Mol. Med., 8(4) (Suppl.):S68-S73, 2002 (review). In one embodiment of the method the virus is a replication-competent oncolytic virus. In a more specific embodiment it is a Paramyxovirus, for example a Newcastle Disease Virus. When utilizing a replication-competent Newcastle Disease Virus, a mesogenic strain is preferred. In another embodiment the oncolytic virus is a Rhabdovirus, for example a Vesicular Stomatitis Virus. In progressively more specific embodiments of the multi-step desensitization method of this invention, and especially when the virus is a replication-competent, mesogenic strain of NDV, the first desensitizing dose is at least 1 10 PFU per square meter of patient surface area; at least 3 x 108 PFU per square meter of patient surface area; or at least 1 x 109 PFU per square meter of patient surface area. In progressively more specific embodiments of the multi-step desensitization method of this invention, and especially when the virus is a replication-competent, mesogenic strain of NDV, the second desensitizing dose is at least 3 x 109 PFU per square meter of patient surface area; at least 5.9 x 109 PFU per square meter of patient surface area; or at least 1.2 x 1010 PFU per square meter of patient surface area. In progressively more specific embodiments of the multi-step desensitization method of this invention, and especially when the virus is a replication-competent, mesogenic strain of NDV, the escalated doses are at least 3 x 109 PFU per square meter of patient surface area; at least 5.9 x 109 PFU per square meter of patient surface area; at least 1.2 x 1010 PFU per square meter of patient surface area; at least 2.4 x 1010 PFU per square meter of patient surface area; at least 4.8 x 1010 PFU per square meter of patient surface area; at least 9.6 x 1010 PFU per square meter of patient surface area; at least 1.2 x 1011 PFU per square meter of patient surface area; at least 1.44 x 1011 PFU per square meter of patient surface area; or at least 1.96 x 1011 PFU per square meter of patient surface area.
In accordance with the multi-step desensitization method of this invention, there is no upper limit on the number of desensitization doses that can be administered. In specific embodiments of the invention the number of desensitization doses administered is two or three. In progressively more specific embodiments of the multi-step desensitization method of this invention in which at least three doses are administered, and especially when the virus is a replication-competent, mesogenic strain of NDV, the third desensitization dose is at least 3 x 109 PFU per square meter of patient surface area; at least 5.9 x 109 PFU per square meter of patient surface area; or at least 1.2 x 1010 PFU per square meter of patient surface area.
In an embodiment of the multi-step desensitization method of this invention, multi- step desensitization can be combined with controlled-rate administration of a given dose of the therapeutic virus. Thus, in accordance with an embodiment of the multi- step desensitization method of this invention, the first desensitization dose: is administered over an administration time period of up to 24 hours; and is administered at a rate of up to 3.0 x 109 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period. In progressively more specific embodiments, the first desensitization dose is administered at a rate of up to 6.7 x 108 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period; or up to 3.3 x 108 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period. In another embodiment of the multi-step desensitization method of this invention, one or more doses selected from the second desensitization dose, a subsequent desensitization dose, if any, and an escalated dose: is administered over an administration time period of less than 24 hours; and is administered at a rate of up to 5.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period. In a more specific embodiment, the second desensitization dose, a subsequent desensitization dose or an escalated dose is administered at a rate of up to 2.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
In accordance with the multi-step desensitization method of this invention, the amount of the virus in the second and any subsequent desensitization dose can be equal to or, preferably, greater than the amount of the virus in the preceding desensitization dose.
In accordance with the multi-step desensitization method of this invention, the therapeutic virus can be administered by any conventional route, for example those disclosed in WO 00/62735. Intravenous administration is preferred.
In accordance with the multi-step desensitization method of this invention, the subject can be a human or a non-human mammal.
In accordance with methods of this invention in which the rate of administration of a therapeutic virus dose is controlled, the method can be utilized with any conventional therapy utilizing a therapeutic virus. Examples of such therapies include oncolytic viruses for the treatment of cancer and the use of viruses in gene therapy, as described for example in WO 94/25627, WO 00/62735, and Kirn, et al., Trends Mol. Med., 8(4) (Suppl.):S68-S73, 2002 (review). In one embodiment of the method the virus is a replication-competent oncolytic virus. In a more specific embodiment it is a Paramyxovirus, for example a Newcastle Disease Virus. When utilizing a replication- competent Newcastle Disease Virus, a mesogenic strain is preferred. In another embodiment the oncolytic virus is a Rhabdovirus, for example a Vesicular Stomatitis Virus.
In accordance with methods of this invention in which the rate of administration of a therapeutic virus dose is controlled, the therapeutic virus can be administered by any conventional route, for example those disclosed in WO 00/62735. Intravenous administration is preferred.
In accordance with methods of this invention in which the rate of administration of a therapeutic virus dose is controlled, the subject can be a human or a non-human mammal.
In accordance with methods of this invention in which the rate of administration of a therapeutic virus dose is controlled, the administration time period is from 1 hour to 24 hours. In a more specific embodiment, the administration time period is from 3 hours to 24 hours.
In progressively more specific further embodiments of the method of this invention in which the rate of administration of the first dose in a cycle of the therapeutic virus is controlled, and especially when the virus is a replication-competent, mesogenic strain of Newcastle Disease Virus, the rate of the first dose is up to 6.7 x 108 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period; or up to 3.3 x 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period. In progressively more specific further embodiments of the method of this invention in which the rate of administration of the first dose of the therapeutic virus is controlled, and especially when the virus is a replication-competent, mesogenic strain of Newcastle Disease Virus, the amount of virus in the first dose is at least 1 x 108 PFU per square meter of patient surface area; at least 3 x 108 PFU per square meter of patient surface area; or at least 1 x 109 PFU per square meter of patient surface area.
In a more specific further embodiment of the method of this invention in which the rate of administration of the second or subsequent dose in a cycle of the therapeutic virus is controlled, and especially when the virus is a replication-competent, mesogenic strain of Newcastle Disease Virus, the rate of the second or subsequent dose is up to 2.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period. In progressively more specific further embodiments of the method of this invention in which the rate of administration of the second or subsequent dose of the therapeutic virus is controlled, and especially when the virus is a replication-competent, mesogenic strain of Newcastle Disease Virus, the amount of virus in the second or subsequent dose is at least 3 x 109 PFU per square meter of patient surface area; at least 5.9 x 109 PFU per square meter of patient surface area; at least 1.2 x 1010 PFU per square meter of patient surface area; at least 2.4 x 1010 PFU per square meter of patient surface area; at least 4.8 x 1010 PFU per square meter of patient surface area; at least 9.6 x 1010 PFU per square meter of patient surface area; at least 1.2 x 1011 PFU per square meter of patient surface area; at least 1.44 x 1011 PFU per square meter of patient surface area; or at least 1.96 x 10u PFU per square meter of patient surface area.
The volume, and hence the concentration, for a therapeutic virus dose generally is not critical. Nevertheless, when choosing a volume the rate of administration should be taken into account. If the volume is too small, it may be difficult to infuse over a long period of time. When administration is to take place over a time period of thirty minutes or more, it has been found convenient to dilute virus doses of less than 4.8 x 1010 PFU/m2 in 25 ml to 100 ml or even greater volumes of saline. For virus doses of greater than 4.8 x 1010 PFU/m2 dilution in 50 ml to 250 ml or even greater volumes of saline is convenient.
The invention will be better understood by reference to the following examples, which illustrate but do not limit the invention described herein. In the following examples the NDV used was a triple-plaque purified attenuated (mesogenic) version of the MK107 strain of Newcastle Disease Vims, described more fully in International Patent Publication WO 00/62735, published October 26, 2000 (Pro- Virus, Inc.). The entire contents of WO 00/62735 and WO 94/25627 are hereby incorporated herein by reference.
EXAMPLES
EXAMPLE 1
Adults with advanced solid tumors, good performance status and adequate end-organ function were treated. PPMK107, a mesogenic Newcastle disease virus strain, as disclosed in WO 00/62735, was given intravenously 3 times per week for 1 week cycled every 4 weeks. Patients were given an initial desensitization dose of 1.2 x 1010 PFU/m2 followed by higher doses ranging from 2.4 to 9.6 x 1010 PFU/m2. This approach therefore used a "Single Step Desensitization". Doses 2-3 were constant in each patient, but escalated by cohort (Table 1). In this example, the first dose of 1.2 x 1010 PFU/m2 was administered over 10 minutes, the doses of 2.4 to 4.8 x 1010 PFU/m2 was given over 10 minutes and the dose of 9.6 x 1010 PFU/m2 was given over 10 to 20 minutes.
Table 1. Dose Levels and Patient Number by Cohort
Cohort Dose 1 Doses 2 - 3 Number of patients
1 1.2 x l0lu PFU/m2 2.4 x 10ιυ PFU/m2 4
2 1.2 x lO10 PFU/m2 4.8 x 1010 PFU/m2, 3
3 1.2 x lO10 PFU/m2 7.2 x 1010 PFU/m2, 5
4 1.2 x lO10 PFU/m2 9.6 x lO11 PFU/m2, 12
EXAMPLE 2
Adults with advanced, solid tumors, good performance status and adequate end-organ function were treated. PPMK107, a mesogenic Newcastle disease virus strain, as disclosed in WO 00/62735, was given intravenously over 30 minutes, 6 times in 2 weeks, cycled every 21 days. 4 dose levels were studied. In each cohort, the 1st and 2nα doses were 1 x 10y PFUmr and 1.2 x 101i0υ - FFU/πf , respectively. Doses 3-6 were constant in each patient, but escalated by cohort beginning at a level of 2.4 1010 PFU/m2 (Table 2). This approach therefore used a "2-Step Desensitization". Dose limiting toxicity (DLT) was defined as any drug-related toxicity of grade 3/4 seen during cycle 1.
Table 2. Dose Levels and Patient Number by Cohort
Cohort Dose 1 Dose 2 Doses 3 - 6 Number of patients
1 1 x 109 PFU/m2 1.2 x 10ιυ PFU/m2 2.4 x 10ιυ PFU/m2 3~
2 1 x lO9 PFU/m2 1.2 x 1010 PFU/m2 4.8 x 1010 PFU/m2, 3
3 1 x lO9 PFU/m2 1.2 x 1010 PFU/m2 9.6 x 1010 PFU/m2, 4
4 l x lO9 PFU/m2 1.2 x 1010 PFU/m2 1.2 x 1011 PFU/m2, 3
Results: Thirteen cancer patients have been enrolled (7 males; median age 58 years; cancer types: 5 colorectal; 2 each breast, sarcoma, ovary; 1 each non-small cell lung, anal). First dose toxicity consisted of flu-like symptoms lasting < 72 hours, all grade 2 or less, and less severe than those seen using single-step desensitization and a first dose of 1.2 x 1010 PFU/m2 (Example 1). The improved safety profile of the 2-step desensitization described in this example is best illustrated by Table 3 below which compares the incidence of grade 3 adverse events seen using these 2 different approaches. No DLTs have been observed. Median number of cycles delivered = 2 (range <1 to 8). Of 10 patients evaluable for response, five had stable disease, and five had progressive disease.
Table 3. Comparison of Incidence of Grade 3 (Severe) Adverse Events Seen in Patients Administered the Two-Step Desensitization of Example 2 versus the One- Step Desensitization of Example 1.
Figure imgf000011_0001
EXAMPLE 3
Adults with advanced, incurable solid tumors, good performance statas and adequate end-organ function are treated. PPMK107, a mesogenic Newcastle disease virus strain, as disclosed in WO 00/62735, is given intravenously, 6 times in 2 weeks, cycled every 21 days. The first dose is given over 3 hours and subsequent doses are given over 1 hour. Three different dose levels are included in this example. At each dose level, the 1st dose is a desensitizing dose for the higher doses. Doses 2-6 were constant in each patient (Table 4). This approach therefore uses a "Single Step Desensitization"
Table 4. Dose Levels
Dose Dose 1 Time of Doses 2 - 6 Time of
Level Infusion For Infusion for Dose 1 Doses 2-6
1 1.2 l0ιυ PFU/m 3 hours 2.4 x 10ιυ PFU/m2 1 hour
2 2.4 x 1010 PFU/m2 3 hours 4.8 x 1010 PFU/m2, 1 hour
3 2.4 x 1010PFU/m2 3 hours 1.2 x lO11 PFU/m2, 1 hour

Claims

CLAIMSWhat is claimed is:
1. A method for administering a therapeutic virus to a subject in one or more cycles, wherein at least one cycle comprises administering sequentially two or more desensitization doses of the virus followed by administering one or more escalated doses of the virus, wherein: the virus is a negative-stranded RNA virus; the amount of the virus in the second and any subsequent desensitization dose is not less than the amount of the virus in the preceding desensitization dose; and the amount of the virus in each of the one or more escalated doses is higher than the amount of virus in each of the desensitization doses.
2. The method of claim 1, wherein the virus is a replication-competent oncolytic virus.
3. The method of claim 2, wherein the oncolytic virus is a Paramyxo virus.
4. The method of claim 3, wherein the Paramyxovirus is a Newcastle Disease Virus.
5. The method of claim 4, wherein the virus is a mesogenic strain of Newcastle Disease Virus.
6. The method of claim 5, wherein the first desensitizing dose is at least 1 x 108 PFU per square meter of patient surface area.
7. The method of claim 6, wherein the first desensitizing dose is at least 3 x 10 PFU per square meter of patient surface area.
8. The method of claim 7, wherein the first desensitizing dose is at least 1 x 10 PFU per square meter of patient surface area.
9. The method of claim 5, wherein the second desensitizing dose is at least 3 x 109 PFU per square meter of patient surface area.
10. The method of claim 9, wherein the second desensitizing dose is at least 5.9 x 109 PFU per square meter of patient surface area.
11. The method of claim 10, wherein the second desensitizing dose is at least 1.2 x 10 PFU per square meter of patient surface area.
12. The method of claim 5, wherein the escalated doses are each at least 3 x 109 PFU per square meter of patient surface area.
13. The method of claim 12, wherein the escalated doses are at least 5.9 x 109 PFU per square meter of patient surface area.
14. The method of claim 13, wherein the escalated doses are at least 1.2 x 1010 PFU per square meter of patient surface area.
15. The method of claim 14, wherein the escalated doses are at least 2.4 x 1010 PFU per square meter of patient surface area.
16. The method of claim 15, wherein the escalated doses are at least 4.8 x 1010 PFU per square meter of patient surface area.
17. The method of claim 16, wherein the escalated doses are at least 9.6 x 1010 PFU per square meter of patient surface area.
18. The method of claim 17, wherein the escalated doses are at least 1.2 x 1011 PFU per square meter of patient surface area.
19. The method of claim 18, wherein the escalated doses are at least 1.44 x 1011 PFU per square meter of patient surface area.
20. The method of claim 19, wherein the escalated doses are at least 1.96 x 1011 PFU per square meter of patient surface area.
21. The method of claim 5, wherein the number of desensitization doses administered is two.
22. The method of claim 5, wherein the number of desensitization doses administered is at least three.
23. The method of claim 22, wherein the third desensitization dose is at least 3 x 109 PFU per square meter of patient surface area.
24. The method of claim 23, wherein the third desensitization dose is at least 5.9 x 10 PFU per square meter of patient surface area.
25. The method of claim 24, wherein the third desensitization dose is at least 1.2 x 1010 PFU per square meter of patient surface area.
26. The method of claim 5, wherein the first desensitization dose: is administered over an administration time period of up to 24 hours; and is administered at a rate of up to 3.0 x 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
27. The method of claim 26, wherein the rate is up to 6.7 x 108 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
28. The method of claim 27, wherein the rate is up to 3.3 x 108 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
29. The method of claim 5, wherein one or more doses selected from the second desensitization dose, any subsequent desensitization dose and an escalated dose: is administered over an administration time period of less than 24 hours; and is administered at a rate of up to 5.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
30. The method of claim 29, wherein the rate is up to 2.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
31. The method of claim 2, wherein the oncolytic virus is a Rhabdo virus.
32 The method of claim 31, wherein the Rhabdovirus is a Vesicular Stomatitis Virus.
33. The method of claim 1, wherein the amount of the virus in the second and any subsequent desensitization dose is greater than the amount of the virus in the preceding desensitization dose.
34. The method of claim 1, wherein the virus is administered to the subject intravenously.
35. The method of claim 1, wherein the subject is a human subject.
36. The method of claim 1, wherein the subject is a non-human mammal.
37. A method for administering a dose of a therapeutic virus to a subject, wherein: the virus is a negative-stranded RNA virus; the dose is the first dose in a cycle comprising one or more doses of the virus; the dose is administered over an administration time period of up to 24 hours; and the dose is administered at a rate of up to 3.0 x 109 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
38. The method of claim 37, wherein the rate is up to 6.7 x 10 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
39. The method of claim 38, wherein the rate is up to 3.3 x 108 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
40. The method of claim 37, wherein the virus is a replication-competent oncolytic virus.
41. The method of claim 40, wherein the oncolytic virus is a Paramyxo virus.
42. The method of claim 41, wherein the Paramyxovirus is a Newcastle Disease Virus.
43. The method of claim 42, wherein the virus is a mesogenic strain of Newcastle Disease Virus.
44. The method of claim 43, wherein the first dose is at least 1 x 10 PFU per square meter of patient surface area.
45. The method of claim 44, wherein the first dose is at least 3 x 10 PFU per square meter of patient surface area.
46. The method of claim 45, wherein the first dose is at least 1 x 109 PFU per square meter of patient surface area.
47. The method of claim 37, wherein the virus is administered to the subject intravenously.
48. The method of claim 37, wherein the subject is a human subject.
49. The method of claim 37, wherein the subject is a non-human mammal.
50. The method of claim 37, wherein the administration time period is at least 1 hour.
51. The method of claim 50, wherein the administration time period is at least 3 hours.
52. A method for administering a dose of a therapeutic virus to a subject, wherein: the virus is a negative-stranded RNA virus; the dose is the second or subsequent dose in a cycle comprising two or more doses of the virus; the dose is administered over an administration time period of up to 24 hours; and the dose is administered at a rate of up to 5.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
53. The method of claim 52, wherein the rate is up to 2.0 x 1010 PFU per square meter of patient surface area in any ten minute sampling time period within the administration time period.
54. The method of claim 52, wherein the virus is a replication-competent oncolytic virus.
55. The method of claim 54, wherein the oncolytic virus is a Paramyxovirus.
56. The method of claim 55, wherein the Paramyxovirus is a Newcastle Disease Virus.
57. The method of claim 56, wherein the virus is a mesogenic strain of Newcastle Disease Virus.
58. The method of claim 57, wherein the second or subsequent dose is at least 3 x 109 PFU per square meter of patient surface area.
59. The method of claim 58, wherein second or subsequent dose is at least 5.9 x 109 PFU per square meter of patient surface area.
60. The method of claim 59, wherein the second or subsequent dose is at least 1.2 x 1010 PFU per square meter of patient surface area.
61. The method of claim 60, wherein the second or subsequent dose is at least 2.4 x 1010 PFU per square meter of patient surface area.
62. The method of claim 61, wherein the second or subsequent dose is at least 4.8 x 1010 PFU per square meter of patient surface area.
63. The method of claim 62, wherein the second or subsequent dose is at least 9.6 x
1010 PFU per square meter of patient surface area.
64. The method of claim 63, wherein the second or subsequent dose is at least 1.2 x
1011 PFU per square meter of patient surface area.
65. The method of claim 64, wherein the second or subsequent dose is at least 1.44 x 1011 PFU per square meter of patient surface area.
66. The method of claim 65, wherein the second or subsequent dose is at least 1.96 x 1011 PFU per square meter of patient surface area.
67. The method of claim 52, wherein the virus is administered to the subject intravenously.
68. The method of claim 52, wherein the subject is a human subject.
69. The method of claim 52, wherein the subject is a non-human mammal.
70. The method of claim 52, wherein the administration time period is at least 1 hour.
71. The method of claim 70, wherein the administration time period is at least 3 hours.
PCT/US2003/016474 2002-06-21 2003-05-22 Administration of therapeutic viruses Ceased WO2004000209A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
NZ537255A NZ537255A (en) 2002-06-21 2003-05-22 Administration of therapeutic viruses
AU2003243307A AU2003243307B2 (en) 2002-06-21 2003-05-22 Administration of therapeutic viruses
CA002489523A CA2489523A1 (en) 2002-06-21 2003-05-22 Administration of therapeutic viruses
US10/518,732 US20050220818A1 (en) 2002-06-21 2003-05-22 Administration of therapeutic viruses
MXPA04012881A MXPA04012881A (en) 2002-06-21 2003-05-22 Administration of therapeutic viruses.
EP03761032A EP1539230A4 (en) 2002-06-21 2003-05-22 Administration of therapeutic viruses
JP2004515715A JP2006511450A (en) 2002-06-21 2003-05-22 Administration of therapeutic virus
IL16586004A IL165860A0 (en) 2002-06-21 2004-12-19 Administration of therapeutic viruses
US12/409,711 US20090180993A1 (en) 2002-06-21 2009-03-24 Administration of therapeutic viruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39063202P 2002-06-21 2002-06-21
US60/390,632 2002-06-21

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/409,711 Continuation US20090180993A1 (en) 2002-06-21 2009-03-24 Administration of therapeutic viruses

Publications (2)

Publication Number Publication Date
WO2004000209A2 true WO2004000209A2 (en) 2003-12-31
WO2004000209A3 WO2004000209A3 (en) 2005-03-03

Family

ID=30000590

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/016474 Ceased WO2004000209A2 (en) 2002-06-21 2003-05-22 Administration of therapeutic viruses

Country Status (11)

Country Link
US (2) US20050220818A1 (en)
EP (2) EP1539230A4 (en)
JP (1) JP2006511450A (en)
AU (1) AU2003243307B2 (en)
CA (1) CA2489523A1 (en)
IL (1) IL165860A0 (en)
MX (1) MXPA04012881A (en)
NZ (1) NZ537255A (en)
RU (1) RU2314830C2 (en)
WO (1) WO2004000209A2 (en)
ZA (1) ZA200410229B (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113018A2 (en) 2004-04-27 2005-12-01 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
WO2021258008A1 (en) * 2020-06-19 2021-12-23 Immunacor Llc Compositions and methods for treating and preventing viral infection

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2379055C1 (en) * 2008-04-30 2010-01-20 Виктор Владимирович Кешелава Method of treating oncological diseases
US8859256B2 (en) 2011-10-05 2014-10-14 Genelux Corporation Method for detecting replication or colonization of a biological therapeutic
WO2013138522A2 (en) 2012-03-16 2013-09-19 Genelux Corporation Methods for assessing effectiveness and monitoring oncolytic virus treatment
WO2013158265A1 (en) 2012-04-20 2013-10-24 Genelux Corporation Imaging methods for oncolytic virus therapy
US20140140959A1 (en) 2012-10-05 2014-05-22 Aladar A. Szalay Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes
WO2015103438A2 (en) 2014-01-02 2015-07-09 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
BR112017007765B1 (en) 2014-10-14 2023-10-03 Halozyme, Inc COMPOSITIONS OF ADENOSINE DEAMINASE-2 (ADA2), VARIANTS THEREOF AND METHODS OF USING THE SAME
MX2018012472A (en) 2016-04-15 2019-08-12 Alpine Immune Sciences Inc Icos ligand variant immunomodulatory proteins and uses thereof.
IL310729A (en) 2016-04-15 2024-04-01 Alpine Immune Sciences Inc Cd80 variant immunomodulatory proteins and uses thereof
US11471488B2 (en) 2016-07-28 2022-10-18 Alpine Immune Sciences, Inc. CD155 variant immunomodulatory proteins and uses thereof
WO2018022945A1 (en) 2016-07-28 2018-02-01 Alpine Immune Sciences, Inc. Cd112 variant immunomodulatory proteins and uses thereof
EP3491013A1 (en) 2016-07-28 2019-06-05 Alpine Immune Sciences, Inc. Cd155 variant immunomodulatory proteins and uses thereof
AU2017345764A1 (en) 2016-10-20 2019-05-02 Alpine Immune Sciences, Inc. Secretable variant immunomodulatory proteins and engineered cell therapy
CA3052473A1 (en) 2017-02-09 2018-08-16 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and compositions and methods thereof
IL320149A (en) 2017-03-16 2025-06-01 Alpine Immune Sciences Inc Immune modulator proteins and PD–L1 variants and their uses
JP2020511144A (en) 2017-03-16 2020-04-16 アルパイン イミューン サイエンシズ インコーポレイテッド PD-L2 variant immunomodulatory proteins and uses thereof
EP3596114A2 (en) 2017-03-16 2020-01-22 Alpine Immune Sciences, Inc. Cd80 variant immunomodulatory proteins and uses thereof
JP7282760B2 (en) 2017-10-18 2023-05-29 アルパイン イミューン サイエンシズ インコーポレイテッド Variant ICOS ligand immunomodulatory proteins and related compositions and methods
WO2019136179A1 (en) 2018-01-03 2019-07-11 Alpine Immune Sciences, Inc. Multi-domain immunomodulatory proteins and methods of use thereof
CA3177467A1 (en) 2018-06-04 2019-12-12 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US11505782B2 (en) 2018-06-04 2022-11-22 Calidi Biotherapeutics, Inc. Cell-based vehicles for potentiation of viral therapy
US12065476B2 (en) 2018-06-15 2024-08-20 Alpine Immune Sciences, Inc. PD-1 variant immunomodulatory proteins and uses thereof
US11242528B2 (en) 2018-08-28 2022-02-08 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN113271955A (en) 2018-11-06 2021-08-17 卡利迪生物治疗有限公司 Enhanced systems for cell-mediated oncolytic viral therapy
US12410402B2 (en) 2018-11-21 2025-09-09 Indapta Therapeutics, Inc. Methods for expansion of natural killer (NK) cell subset and related compositions and methods
JP7713886B2 (en) 2018-11-30 2025-07-28 アルパイン イミューン サイエンシズ インコーポレイテッド CD86 variant immunomodulatory proteins and uses thereof
CA3131017C (en) 2019-02-27 2025-05-13 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
US12024709B2 (en) 2019-02-27 2024-07-02 Actym Therapeutics, Inc. Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment
AU2021258194A1 (en) 2020-04-22 2022-11-24 Indapta Therapeutics, Inc. Natural killer (NK) cell compositions and methods for generating same
WO2022147481A1 (en) 2020-12-30 2022-07-07 Ansun Biopharma Inc. Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062735A2 (en) 1999-04-15 2000-10-26 Pro-Virus, Inc. Treatment of neoplasms with viruses

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3906092A (en) * 1971-11-26 1975-09-16 Merck & Co Inc Stimulation of antibody response
PT696326E (en) * 1993-04-30 2003-08-29 Wellstat Biologics Corp UTILIZATION OF NDV IN THE MANUFACTURE OF A CANCER TREATMENT MEDICINE
DE69434594T2 (en) * 1993-10-25 2006-09-21 Canji, Inc., San Diego RECOMBINANT ADENOVIRUS VECTOR AND METHOD OF USE
EP0848956A1 (en) * 1996-12-17 1998-06-24 Dimminaco Ag/Sa/Ltd. In ovo vaccination against Newcastle Disease
US7470426B1 (en) * 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
NZ503664A (en) * 1997-10-09 2002-08-28 Pro Virus Inc A method for purifying an RNA virus comprising generating a clonal virus and purifying the clonal virus by ultracentrifugation without pelleting
US6024961A (en) * 1997-11-14 2000-02-15 Washington University Recombinant avirulent immunogenic S typhi having rpos positive phenotype
US20050074901A1 (en) * 2002-02-13 2005-04-07 John Castracane Methods and assays for detecting and quantifying the human p53 inducible gene protein
EP1578451A4 (en) * 2002-11-05 2007-01-24 Wellstat Biologics Corp Treating carcinoid neoplasms with therapeuthic viruses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062735A2 (en) 1999-04-15 2000-10-26 Pro-Virus, Inc. Treatment of neoplasms with viruses

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. CLIN. ONCOL., vol. 20, May 2002 (2002-05-01), pages 2251 - 2266
See also references of EP1539230A4

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113018A2 (en) 2004-04-27 2005-12-01 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US9844574B2 (en) 2004-04-27 2017-12-19 Wellstat Biologics Corporation Cancer treatment using viruses and camptothecins
US7767200B2 (en) 2005-07-14 2010-08-03 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
US8377450B2 (en) 2009-11-30 2013-02-19 United Cancer Research Institute Clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
WO2021258008A1 (en) * 2020-06-19 2021-12-23 Immunacor Llc Compositions and methods for treating and preventing viral infection

Also Published As

Publication number Publication date
EP1539230A4 (en) 2007-10-31
EP1539230A2 (en) 2005-06-15
JP2006511450A (en) 2006-04-06
US20050220818A1 (en) 2005-10-06
US20090180993A1 (en) 2009-07-16
CA2489523A1 (en) 2003-12-31
RU2314830C2 (en) 2008-01-20
IL165860A0 (en) 2006-01-15
AU2003243307B2 (en) 2010-04-01
WO2004000209A3 (en) 2005-03-03
EP2266601A1 (en) 2010-12-29
MXPA04012881A (en) 2005-07-05
AU2003243307A1 (en) 2004-01-06
RU2005101351A (en) 2005-08-10
ZA200410229B (en) 2006-07-26
NZ537255A (en) 2009-04-30

Similar Documents

Publication Publication Date Title
AU2003243307B2 (en) Administration of therapeutic viruses
Markert et al. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12
US20160303175A1 (en) Cancer Treatment Using Viruses and Camptothecins
Ford et al. Immunization of rats against Schistosoma mansoni using irradiated cercariae, lung schistosomula and liver-stage worms
CN110876759A (en) Application of M gene mutated vesicular stomatitis virus in antitumor drugs
JP5190958B2 (en) Treatment of cancer using viruses, fluoropyrimidine and camptothecin
US9623096B2 (en) Virally infected hematopoietic cells and uses thereof
AU2004266102B2 (en) Anti-cancer virus desensitization method
Youngner et al. Interferon production in mice by vesicular stomatitis virus
Todd et al. Influence of epinephrine upon plasma potassium concentration: Changes with time during constant infusion
Santoro et al. The relationship between prostaglandins and virus replication: endogenous prostaglandin synthesis during infection and the effect of exogenous PGA on virus production in different cell lines and in persistently infected cells
KR20060007006A (en) Newcastle disease virus administration method
Li et al. Studies on inhibition of viral oncogenesis: III. Effect of clam extracts and methotrexate on tumor formation in male and female hamsters induced by virulent and attenuated Adenovirus-12
AU2004233804A1 (en) Treating hepatocellular carcinomas using therapeutic viruses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003243307

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2489523

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 537255

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/012881

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 165860

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 10518732

Country of ref document: US

Ref document number: 200410229

Country of ref document: ZA

Ref document number: 2004515715

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038145847

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2005101351

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2003761032

Country of ref document: EP

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWP Wipo information: published in national office

Ref document number: 2003761032

Country of ref document: EP